Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Leber's congenital amaurosis (LCA) is a group of inherited blinding diseases with onset during childhood. One form of the disease, LCA2, is caused by mutations in the retinal pigment epithelium-specific 65-kDa protein gene (RPE65). We investigated the safety of subretinal delivery of a recombinant adeno-associated virus (AAV) carrying RPE65 complementary DNA (cDNA) (ClinicalTrials.gov number, NCT00516477 [ClinicalTrials.gov]). Three patients with LCA2 had an acceptable local and systemic adverse-event profile after delivery of AAV2.hRPE65v2. Each patient had a modest improvement in measures of retinal function on subjective tests of visual acuity. In one patient, an asymptomatic macular hole developed, and although the occurrence was considered to be an adverse event, the patient had some return of retinal function. Although the follow-up was very short and normal vision was not achieved, this study provides the basis for further gene therapy studies in patients with LCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The main disadvantage of this approach is the surgery itself. Traditional vitrectomy complications such as cataract, IOP rise and retinal tears, as well as subretinal injection-related complications such as a macular hole.4,87,88”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [88]
In the citing paper
“Many current retinal gene therapy trials adopt a standardized immunosuppression protocol up to 21 days post-treatment, which may ameliorate this immune response in humans.6,7,40”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [40]
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [42]
In the citing paper
“during Phase I/II clinical trials for Leber's congenital amaurosis (LCA), over 30 patients who received a subretinal injection of AAV2 encoding RPE65, an enzyme responsible for the isomerohydrolase activity of retinal pigment epithelium, showed sustained improvement in both subjective and objective measurements of vision.8–14”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
In the citing paper
“As a result, AAV clinical successes to date have involved delivery either to immune privileged regions or to subjects lacking apparent AAV immunological memory.8–14,30,42”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationIdiopathic Senile Macular Hole: Its Early Stages and Pathogenesis
Gass, J. D. M. (1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060130683026 · Cited by 992
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Self-citationMutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
RPE65 is the isomerohydrolase in the retinoid visual cycle
Moiseyev, G., Chen, Y., Takahashi, Y., Wu, B. X., & Ma, J.-X. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503460102 · Cited by 536
Self-citationAcland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
Self-citationRpe65 is the retinoid isomerase in bovine retinal pigment epithelium
Jin, M., Li, S., Moghrabi, W. N., Sun, H., & Travis, G. H. (2005) · Cell · doi:10.1016/j.cell.2005.06.042 · Cited by 424
Redmond, T. M., Poliakov, E., Yu, S., Tsai, J.-Y., Lu, Z., & Gentleman, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504167102 · Cited by 409
Self-citationNatural Course of Retinitis Pigmentosa Over a Three-Year Interval
Berson, E. L., Sandberg, M. A., Rosner, B., Birch, D. G., & Hanson, A. H. (1985) · American Journal of Ophthalmology · doi:10.1016/0002-9394(85)90351-4 · Cited by 321
Jacobson, S. G., Aleman, T. S., Cideciyan, A. V., Sumaroka, A., Schwartz, S. B., Windsor, E. A. M., Traboulsi, E. I., Heon, E., Pittler, S. J., Milam, A. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500646102 · Cited by 274
Self-citation
Research works printed but not linked: 4
- Lorenz B, 2000, Invest Ophthalmol Vis Sci, 41, 2735
- Aguirre GD, 1998, Mol Vis, 4, 23
- 10.1038/88327 · DOI
- Fosnaugh JS, 1992, Methods Find Exp Clin Pharmacol, 14, 545
Cited by
Items 801–900 of 1,031
Current and future treatment approaches for Barth syndrome
Thompson, R., Jefferies, J. L., Wang, S., Pu, W. T., Takemoto, C. M., Hornby, B., Heyman, A., Chin, M. T., & Vernon, H. J. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12453 · Cited by 41
“These therapies, based on gene delivery by recombinant adeno-associated virus (AAV), have demonstrated remarkable efficacy and safety.(69,70) AAV is also the current viral vector of choice for delivery of therapeutic cargo to heart and skeletal muscle,(68) major tissues affected in Barth syndrome.”
BackgroundXi, Z., Vats, A., Sahel, J., Chen, Y., & Byrne, L. C. (2022) · Nature Communications · doi:10.1038/s41467-022-35361-8 · Cited by 44
Enhancing pediatric access to cell and gene therapies
Mackall, C. L., Bollard, C. M., Goodman, N., Carr, C., Gardner, R., Rouce, R. H., Sotillo, E., Stoner, R., Urnov, F. D., Wayne, A. S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03035-1 · Cited by 44
“Voretigene neparvovec-ryzl (Luxturna), a locally administered gene replacement therapy for Leber’s congenital amaurosis, can restore sight in adults and children with congenital blindness 3,4 .”
Establishment and evolution of the A ustralian I nherited R etinal D isease R egister and DNA B ank
Roach, J. N. D., McLaren, T. L., Paterson, R. L., O'Brien, E. C., Hoffmann, L., Mackey, D. A., Hewitt, A. W., & Lamey, T. M. (2012) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12020 · Cited by 42
Han, Z., Conley, S. M., & Naash, M. I. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6916 · Cited by 40
“In an effort to design optimum treatments, each group chose a different promoter to drive RPE65 gene expression; Maguire et al.(4) used a chicken beta actin (CBA) promoter, Bainbridge et al.”
BackgroundEngineering Visual Arrestin-1 with Special Functional Characteristics
Vishnivetskiy, S. A., Chen, Q., Palazzo, M. C., Brooks, E. K., Altenbach, C., Iverson, T. M., Hubbell, W. L., & Gurevich, V. V. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445437 · Cited by 42
Igarashi, T., Miyake, K., Masuda, I., Takahashi, H., & Shimada, T. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.153 · Cited by 40
“These three trials are similar in that they all investigated the efficacy of using AAV type 2 vector-mediated gene transfer to treat Leber’s congenital amaurosis, a severe inherited form of early-onset retinal degeneration (Maguire et al. , 2008).”
Murakami, Y., Ikeda, Y., Yonemitsu, Y., Miyazaki, M., Inoue, M., Hasegawa, M., Sueishi, K., & Ishibashi, T. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.102 · Cited by 40
“…and efficacy of the subretinal delivery of rAAV carrying the RPE65 gene for patients with Leber’s congenital amaurosis, thereby providing the proof of concept for retinal gene therapy strategies (Bainbridge et al. , 2008; Hauswirth et al. , 2008; Maguire et al. , 2008; Cideciyan et al. , 2009).”
Pearson, R. A., Hippert, C., Graca, A. B., & Barber, A. C. (2014) · Visual Neuroscience · doi:10.1017/s0952523814000200 · Cited by 41
“Such strategies have been used successfully for the administration of viral vectors for gene replacement therapy in patients (Bainbridge et al., 2008 ; Maguire et al., 2008 ).”
MethodNon‐viral retinal gene therapy: a review
Issa, P. C., & MacLaren, R. E. (2012) · Clinical & Experimental Ophthalmology · doi:10.1111/j.1442-9071.2011.02649.x · Cited by 39
Contemporary Animal Models For Human Gene Therapy Applications
Gopinath, C., Nathar, T. J., Ghosh, A., Hickstein, D. D., & Nelson, E. J. R. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150929110424 · Cited by 49
Tian, L., Yang, P., Lei, B., Shao, J., Wang, C., Xiang, Q., Lin, W., Peng, Z., & Kijlstra, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019542 · Cited by 41
“Currently, gene therapy has achieved remarkable success in human and animal models in various retinal diseases [11,12,13,14].”
BackgroundHost and Vector-dependent Effects on the Risk of Germline Transmission of AAV Vectors
Favaro, P., Downey, H. D., Zhou, J. S., Wright, J. F., Hauck, B., Mingozzi, F., High, K. A., & Arruda, V. R. (2009) · Molecular Therapy · doi:10.1038/mt.2009.56 · Cited by 40
Self-citationSundaresan, P., Vijayalakshmi, P., Thompson, S., Ko, A. C., Fingert, J. H., & Stone, E. M. (2009) · PubMed Central · Cited by 40
Self-citationHauswirth, W. W., Alemán, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hgt.2008.107 · Cited by 47
Vasconcelos, H. M., Lujan, B. J., Pennesi, M. E., Yang, P., & Lauer, A. K. (2020) · International Journal of Retina and Vitreous · doi:10.1186/s40942-020-00216-1 · Cited by 39
Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S. (2020) · BioDrugs · doi:10.1007/s40259-020-00453-8 · Cited by 41
Xu, H., Zhang, L., Gu, L., Lü, L., Gao, G., Li, W., Xu, G., Wang, J., Gao, F., Xu, J., et al. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13155 · Cited by 40
Kim, J., You, Y. S., Kim, S. H., & Kwon, O. W. (2016) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000000327 · Cited by 40
MiR-124 aggravates failing hearts by suppressing CD151-facilitated angiogenesis in heart
Zhao, Y., Yan, M., Chen, C., Gong, W., Yin, Z., Li, H., Fan, J., Zhang, X. A., Wang, D. W., & Zuo, H. (2018) · Oncotarget · doi:10.18632/oncotarget.24205 · Cited by 40
“Furthermore, the clinical benefits and safety of gene therapy using rAAVs were reported for the treatment of human diseases, such as Leber’s congenital amaurosis [48, 49].”
Lin, A. Z., & Balazs, A. B. (2018) · Retrovirology · doi:10.1186/s12977-018-0449-7 · Cited by 42
Focused ultrasound as a novel strategy for noninvasive gene delivery to retinal Müller glia
Touahri, Y., Dixit, R., Kofoed, R. H., Miloska, K., Park, E., Raeisossadati, R., Markham-Coultes, K., David, L. A., Rijal, H., Zhao, J., et al. (2020) · Theranostics · doi:10.7150/thno.42611 · Cited by 43
“AAV gene therapies have begun to be applied to retinal diseases in clinical trials [13-16], including Lebers congenital amaurosis, for which viral delivery of a corrected RPE65 gene (Luxturna) has been approved [17].”
Gene Therapy Potential for Genetic Disorders of Surfactant Dysfunction
Cooney, A. L., Wambach, J., Sinn, P. L., & McCray, P. B. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.785829 · Cited by 52
“Gene Therapy Approach: Adeno-Associated Virus Vectors AAV vectors have gained interest with increasing clinical applications following the FDA approval of Luxturna (Maguire et al., 2008), Zolgensma (Mendell et al.”
BackgroundPhotoreceptor Sensory Cilia and Inherited Retinal Degeneration
Liu, Q., Zhang, Q., & Pierce, E. A. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1399-9_26 · Cited by 44
“Finding the genetic cause of IRDs has become increasingly important, as the recent reports of early successes with gene therapy for LCA2 indicate that we are entering an era of genetic therapies for IRDs (Maguire et al. 2008).”
BackgroundSelf-citationRole of Molecular Genetics in Hemophilia: From Diagnosis to Therapy
Jayandharan, G. R., Srivastava, A., & Srivastava, A. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0031-1300953 · Cited by 44
Wu, T.-L., Li, H., Faust, S. M., Chi, E., Zhou, S., Wright, F., High, K. A., & Ertl, H. C. (2014) · Molecular Therapy · doi:10.1038/mt.2013.218 · Cited by 38
Self-citationOchakovski, G. A., Peters, T., Michalakis, S., Wilhelm, B., Wissinger, B., Biel, M., Bartz-Schmidt, K. U., Fischer, M. D., & for the RD-CURE Consortium (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22402 · Cited by 38
Immune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I/IIa gene therapy trial
Mishra, A., Vijayasarathy, C., Cukras, C. A., Wiley, H. E., Sen, H. N., Zeng, Y., Wei, L. L., & Sieving, P. A. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.013 · Cited by 38
Hashida, N., & Nishida, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114870 · Cited by 38
Castro, B. F. M., Steel, J. C., & Layton, C. J. (2023) · BioDrugs · doi:10.1007/s40259-023-00629-y · Cited by 42
Sun, D., Maeno, H., Gujrati, M., Schur, R., Maeda, A., Maeda, T., Palczewski, K., & Lu, Z. (2015) · Macromolecular Bioscience · doi:10.1002/mabi.201500192 · Cited by 37
Oligochitosan polyplexes as carriers for retinal gene delivery
Puras, G., Sesma, J. Z., Díaz‐Tahoces, A., Avilés‐Trigueros, M., Fernández, E., & Pedraz, J. L. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.11.009 · Cited by 44
Friedmann, T., Rabin, O., & Frankel, M. (2010) · Science · doi:10.1126/science.1177801 · Cited by 36
Gene therapy for diseases of the cornea – a review
Williams, K. A., & Coster, D. J. (2009) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2009.02179.x · Cited by 39
Wang, J., Zarbin, M. A., Sugino, I. K., Whitehead, I. P., & Townes‐Anderson, E. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19447 · Cited by 39
Outcome Measures Used in Ocular Gene Therapy Trials: A Scoping Review of Current Practice
Jolly, J. K., Bridge, H., & MacLaren, R. E. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01076 · Cited by 38
Gene Therapy for Lung Neoplasms
Vachani, A., Moon, E. K., Wakeam, E., Haas, A. R., Sterman, D. H., & Albelda, S. Μ. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.08.006 · Cited by 40
Stankowska, D. L., Minton, A. Z., Rutledge, M. A., Mueller, B., Phatak, N., He, S., Ma, H., Forster, M. J., Yorio, T., & Krishnamoorthy, R. R. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15008 · Cited by 43
Verrier, J. D., Madorsky, I., Coggin, W. E., Geesey, M., Hochman, M., Walling, E., Daroszewski, D., Eccles, K. S., Ludlow, R., & Semple-Rowland, S. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020553 · Cited by 38
Siemiatkowska, A. M., Arimadyo, K., Moruz, L., Astuti, G., de Castro‐Miró, M., Zonneveld, M. N., Strom, T. M., de Wijs, I. J., Hoefsloot, L. H., Faradz, S. M., et al. (2011) · PubMed Central · Cited by 45
Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain
Sullivan, J. A., Stanek, L. M., Lukason, M. J., Bu, J., Osmond, S. R., Barry, E. A., O’Riordan, C. R., Shihabuddin, L. S., Cheng, S. H., & Scaria, A. (2018) · Gene Therapy · doi:10.1038/s41434-018-0017-8 · Cited by 37
Updates on current advances in gene therapy.
Tani, J., Faustine, & Sufian, J. T. (2011) · PubMed · Cited by 48
Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs
Baylot, V., Le, T. K., Taïeb, D., Rocchi, P., & Colleaux, L. (2024) · Communications Biology · doi:10.1038/s42003-024-06121-9 · Cited by 48
Stem cell therapy for glaucoma: Science or snake oil?
Sun, Y., Williams, A. L., Waisbourd, M., Iacovitti, L., & Katz, L. J. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.07.001 · Cited by 41
“The procedure was deemed by the authors to have an acceptable local and systemic adverse event profile, although one patient did develop an asymptomatic macular hole after the procedure.(80) All patients experienced significant improvements in visual function that has been maintained through 3 years of follow up.”
Applications of antisense oligonucleotides for the treatment of inherited retinal diseases
Collin, R. W. J., & Garanto, A. (2017) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000363 · Cited by 37
Daly, C., Shine, L., Heffernan, T., Deeti, S., Reynolds, A., O'Connor, J. J., Dillon, E., Duffy, D. J., Kölch, W., Cagney, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11513-5 · Cited by 38
Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression
Vidal, P., Pagliarani, S., Colella, P., Verdera, H. C., Jauze, L., Gjorgjieva, M., Puzzo, F., Marmier, S., Collaud, F., Sola, M. S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.019 · Cited by 42
Self-citationCabanes‐Creus, M., Ginn, S. L., Amaya, A. K., Liao, S. H. Y., Westhaus, A., Hallwirth, C. V., Wilmott, P., Ward, J., Dilworth, K. L., Santilli, G., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.016 · Cited by 36
Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations
Talib, M., & Boon, C. J. F. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000290 · Cited by 41
“The first successful gene therapy was applied in patients with RPE65-RD.3 Several trials have found compelling results in other RD subtypes, such as choroideremia,4,5 and many other trials are ongoing (Table 1) or in the basic experimental or preclinical phase.6,7 However, an imbalance exists between the rapid advance…”
Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?
Buttery, P. C., & Barker, R. A. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00940-4 · Cited by 44
Pathogenic mechanisms and the prospect of gene therapy for choroideremia
Dimopoulos, I. S., Chan, S., MacLaren, R. E., & MacDonald, I. M. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1046434 · Cited by 37
“Indeed, a number of past, ongoing and planned clinical trials make use of AAV vector systems for gene delivery in diseases affecting the central nervous system as well as the eye [89-92].”
BackgroundAAV-Mediated Gene Therapy for Retinal Disorders in Large Animal Models
Stieger, K., Lheriteau, E., Moullier, P., & Rolling, F. (2009) · ILAR Journal · doi:10.1093/ilar.50.2.206 · Cited by 37
Wert, K. J., Sancho-Pelluz, J., & Tsang, S. H. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt452 · Cited by 37
Correction of Monogenic and Common Retinal Disorders with Gene Therapy
Sengillo, J., Justus, S., Cabral, T., & Tsang, S. (2017) · Genes · doi:10.3390/genes8020053 · Cited by 37
Sobh, M., Lagali, P. S., Ghiasi, M., Montroy, J. R., Dollin, M. L., Hurley, B. R., Leonard, B. C., Dimopoulos, I. S., Lafreniere, M., Fergusson, D. A., et al. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.11.24 · Cited by 38
Maria, M., Ajmal, M., Azam, M., Waheed, N. K., Siddiqui, S. N., Mustafa, B., Ayub, H., Ali, L., Ahmad, S., Micheal, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119806 · Cited by 39
“For example, AAV-based gene therapy has been shown to be successful in a CRD dog model and in humans with RPE65-associated LCA [52–57], as well as in choroideremia subjects [58].”
BackgroundGarcia, M. M., Ying, G.-S., Cocores, C. A., Tanaka, J. C., & Komáromy, A. M. (2010) · American Journal of Veterinary Research · doi:10.2460/ajvr.71.1.97 · Cited by 40
Charng, J., Cideciyan, A. V., Jacobson, S. G., Sumaroka, A., Schwartz, S. B., Swider, M., Roman, A. J., Sheplock, R., Anand, M., Peden, M. C., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw361 · Cited by 36
Fujita, K., Nishiguchi, K. M., Shiga, Y., & Nakazawa, T. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.003 · Cited by 40
DNA nanoparticles are safe and nontoxic in non-human primate eyes
Kelley, R. A., Conley, S. M., Makkia, R., Watson, J. N., Han, Z., Cooper, M. J., & Naash, M. I. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s157000 · Cited by 36
“23 Current retina/RPE-targeted gene therapies are being delivered subretinally; 24,25 however, this procedure is invasive, and long-term sequelae as a result of the injection procedure are thought to impair the efficacy of the treatment.”
García-Delgado, A. B., Valdés-Sánchez, L., Morillo-Sánchez, M. J., Ponte, B., Diaz-Corrales, F. J. J., & de la Cerda, B. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01843-z · Cited by 40
Mitochondrial medicine: to a new era of gene therapy for mitochondrial DNA mutations
Cwerman‐Thibault, H., Sahel, J., & Corral‐Debrinski, M. (2011) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9131-5 · Cited by 36
“It is tremendously encouraging to see that gene replacement therapy for RPE65 driven by recombinant adeno-associated virus (rAAV2) was safe and effective, even in adults who had severely advanced disease (Bainbridge et al. 2008; Maguire et al. 2008; Cideciyan et al. 2008; Cideciyan et al. 2009b; Maguire et al. 2009).”
BackgroundShao, J., Tian, L., Lei, B., Lin, W., Yang, Y., Kijlstra, A., & Yang, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037773 · Cited by 36
Tan, M. H., Mackay, D. S., Cowing, J. A., Tran, H. V., Smith, A. J., Wright, G., Borman, A. D., Henderson, R., Moradi, P., Russell‐Eggitt, I., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032330 · Cited by 37
Current understanding of usher syndrome type II
Yang, J., Wang, L., Song, H., & Sokolov, M. (2011) · Frontiers in bioscience · doi:10.2741/3979 · Cited by 44
The genetics of eye disorders in the dog
Mellersh, C. S. (2014) · Canine Genetics and Epidemiology · doi:10.1186/2052-6687-1-3 · Cited by 52
“Subretinal injections of adenoassociated virus vectors expressing RPE65 resulted in restoration of rod photoreceptor function and improved visual function, first in dogs [61,62] and subsequently in humans [63-65].”
BackgroundDefining Outcomes for Clinical Trials of Leber Congenital Amaurosis Caused by GUCY2D Mutations
Jacobson, S. G., Cideciyan, A. V., Sumaroka, A., Román, A. J., Charng, J., Lu, M., Choudhury, S., Schwartz, S., Héon, E., Fishman, G. A., et al. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.02.003 · Cited by 39
Impact of Retinal Disease-Associated RPE65 Mutations on Retinoid Isomerization
Bereta, G., Kiser, P. D., Golczak, M., Sun, W., Heon, E., Saperstein, D. A., & Palczewski, K. (2008) · Biochemistry · doi:10.1021/bi800905v · Cited by 36
The application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Hu, X., Zhang, B., Li, X., Li, M., Wang, Y., Dan, H., Zhou, J., Wei, Y., Ge, K., Li, P., et al. (2022) · Eye · doi:10.1038/s41433-022-02169-1 · Cited by 42
“The earliest clinical trial of gene replacement therapy for RPE65-induced LCA achieved good results [46].”
BackgroundGene therapy for genetic diseases: challenges and future directions
Beibei, Q. I. E., Tuo, J., Chen, F., Ding, H., & Lyu, L. (2025) · MedComm · doi:10.1002/mco2.70091 · Cited by 45
Ledley, F. D., McNamee, L. M., Uzdil, V., & Morgan, I. (2013) · Gene Therapy · doi:10.1038/gt.2013.72 · Cited by 37
Present and Future of Adeno Associated Virus Based Gene Therapy Approaches
Ortolano, S., Spuch, C., & Navarro, C. (2012) · Recent Patents on Endocrine, Metabolic & Immune Drug Discovery · doi:10.2174/187221412799015245 · Cited by 35
Adeno-Associated Virus Mediated Gene Therapy for Retinal Degenerative Diseases
Stieger, K., Cronin, T., Bennett, J., & Rolling, F. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_8 · Cited by 35
Self-citationSanjurjo-Soriano, C., & Kalatzis, V. (2018) · Neural Plasticity · doi:10.1155/2018/5056279 · Cited by 43
The Unusual Properties of the AAV Inverted Terminal Repeat
Berns, K. I. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.017 · Cited by 35
Dimopoulos, I. S., Radziwon, A., Laurent, C. D. S., & MacDonald, I. M. (2017) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000392 · Cited by 36
Retinal Gene Delivery by rAAV and DNA Electroporation
Venkatesh, A., Ma, S., Langellotto, F., Gao, G., & Punzo, C. (2013) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc14d04s28 · Cited by 35
“Delivery of the RPE65 gene by rAAV to the RPE of individuals suffering from LCA-2 has restored vision in blind people (Bainbridge et al., 2008; Maguire et al., 2008), giving hope to many others suffering from vision loss.”
BackgroundImaging retinal ganglion cells: Enabling experimental technology for clinical application
Smith, C. A., & Chauhan, B. C. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.10.003 · Cited by 35
Residual Electroretinograms in Young Leber Congenital Amaurosis Patients with Mutations of AIPL1
Pennesi, M. E., Stover, N. B., Stone, E. M., Chiang, P.-W., & Weleber, R. G. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-8298 · Cited by 35
Self-citationOccelli, L. M., Schön, C., Seeliger, M. W., Biel, M., Michalakis, S., & Petersen‐Jones, S. M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.155 · Cited by 37
Curing Color Blindness--Mice and Nonhuman Primates
Neitz, M., & Neitz, M. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017418 · Cited by 38
“Previously, in treating red-green color blindness in primates, virus was injected into the subretinal space (the region between the retinal pigment epithelium and the photoreceptors) because it was the only way to ensure that the virus would have access to photoreceptors; however, subretinal injections carry risk of r…”
BackgroundRoss, A. G., McDougald, D. S., Khan, R. S., Duong, T. T., Dine, K. E., Aravand, P., Bennett, J., Chavali, V. R. M., & Shindler, K. S. (2021) · Gene Therapy · doi:10.1038/s41434-021-00219-z · Cited by 34
Self-citationIntravitreal Injection of Splice-switching Oligonucleotides to Manipulate Splicing in Retinal Cells
Gérard, X., Perrault, I., Munnich, A., Kaplan, J., & Rozet, J.-M. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.24 · Cited by 34
Annear, M. J., Mowat, F. M., Bartoe, J. T., Querubin, J., Azam, S. A., Basche, M., Curran, P. G., Smith, A. J., Bainbridge, J. W. B., Ali, R. R., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.146 · Cited by 34
“There is a similar finding in the RPE65-LCA patients treated by gene augmentation therapy where even in those patients with the greatest improvement in visual function the full-field flash ERG was not improved (Bainbridge et al., 2008; Cideciyan et al., 2008, 2009, 2013; Hauswirth et al., 2008; Maguire et al., 2008; B…”
InfluentialGene Therapy for Mesothelioma and Lung Cancer
Vachani, A., Moon, E. K., Wakeam, E., & Albelda, S. Μ. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0026rt · Cited by 40
Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome
Ayuso, E. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.49 · Cited by 34
Tshilenge, K.-T., Ameline, B., Weber, M., Mendes-Madeira, A., Nedellec, S., Biget, M., Provost, N., Libeau, L., Blouin, V., Deschamps, J.-Y., et al. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.034 · Cited by 34
High-Throughput Dissection of AAV–Host Interactions: The Fast and the Curious
Herrmann, A.-K., & Grimm, D. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.022 · Cited by 38
Chronic Dicer1 deficiency promotes atrophic and neovascular outer retinal pathologies in mice
Wright, C. B., Uehara, H., Kim, Y., Yasuma, T. R., Yasuma, R., Hirahara, S., Makin, R. D., Apicella, I., Pereira, F., Nagasaka, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1909761117 · Cited by 34
“We selected adenoassociated vector (AAV) because this modality has demonstrated safety and efficacy in treating blinding diseases in human patients (43, 44) and in experimental models of CRNV (45–50).”
MethodTissue engineering of the retina: from organoids to microfluidic chips
Marcos, L. F., Wilson, S. L., & Roach, P. (2021) · Journal of Tissue Engineering · doi:10.1177/20417314211059876 · Cited by 37
Retinal amino acid neurochemistry in health and disease
Kalloniatis, M., Loh, C. S., Acosta, M. L., Tomisich, G., Zhu, Y., Nivison‐Smith, L., Fletcher, E. L., Chua, J., Sun, D., & Arunthavasothy, N. (2013) · Clinical and Experimental Optometry · doi:10.1111/cxo.12015 · Cited by 36
Wei, Z., Huang, Y., Zhao, D., Hu, Z., Li, Z., & Liang, Z. (2015) · Scientific Reports · doi:10.1038/srep07618 · Cited by 37
Proteomics Analysis of Co-Purifying Cellular Proteins Associated with rAAV Vectors
Dong, B., Duan, X., Chow, H. Y., Chen, L., Lu, H., Wu, W., Hauck, B., Wright, F., Kapranov, P., & Xiao, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086453 · Cited by 34
“Recombinant AAV (rAAV) has been used in clinical trials for a decade and is believed to represent one of the most promising vectors for gene therapy [2–5].”
MethodSelf-citationProinsulin Slows Retinal Degeneration and Vision Loss in the P23H Rat Model of Retinitis Pigmentosa
Fernández‐Sánchez, L., Lax, P., Isiegas, C., Ayuso, E., Ruiz, J. M., de la Villa, P., Bosch, F., de la Rosa, E. J., & Cuenca, N. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.067 · Cited by 39
“Today, gene therapy for RP has been successfully used in animal models (Chadderton et al. , 2009; Millington-Ward et al. , 2011; Palfi et al. , 2010; Pang et al. , 2011; Pinilla et al. , 2007, 2009) and humans (Bainbridge et al. , 2008; Maguire et al. , 2008, 2009).”
Enhanced selective gene delivery to neural stem cells in vivo by an adeno-associated viral variant
Kotterman, M. A., Vazin, T., & Schaffer, D. V. (2015) · Development · doi:10.1242/dev.115253 · Cited by 36
“AAV vectors have gathered increasing momentum for basic biological investigation (Oh et al., 2014) and for clinical gene delivery (Bainbridge et al., 2008; Kotterman and Schaffer, 2014; MacLaren et al., 2014; Maguire et al., 2008, 2009; Nathwani et al., 2011; Ojala et al., 2015).”
Lisowska, J., Lisowski, Ł., Kelbsch, C., Maeda, F., Richter, P., Kohl, S., Zobor, D., Straßer, T., Stingl, K. T., Zrenner, E., et al. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20505 · Cited by 36
Duong, T. T., Lim, J., Vasireddy, V., Papp, T., Nguyen, H., Leo, L., Pan, J., Zhou, S., Chen, H. I., Bennett, J., et al. (2019) · Stem Cells International · doi:10.1155/2019/7281912 · Cited by 33
Self-citationLohia, A., Sahel, D. K., Salman, M., Singh, V., Mariappan, I., Mittal, A., & Chitkara, D. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.02.001 · Cited by 33
Obstacles and future of gene therapy for hemophilia
Arruda, V. R., & Samelson-Jones, B. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1069179 · Cited by 33
“These procedures aim to replicate the ability of direct introduction of AAV to target tissues such as the eye [9] to avoid preexisting NAbs.”
BackgroundSelf-citationOcular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
Metadata
- Authors
- Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., Rossi, S., Lyubarsky, A., Arruda, V. R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell'Osso, L., Hertle, R., Ma, J.-X., Redmond, T. M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K. S., Maguire, M. G., Wright, J. F., Volpe, N. J., McDonnell, J. W., Auricchio, A., High, K. A., & Bennett, J.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Telethon Institute Of Genetics And Medicine (IT)
- University of Pennsylvania (US)
- University of Iowa (US)
- Veterans Health Administration (US)
- Children's Hospital of Pittsburgh (US)
- University of Oklahoma (US)
- National Eye Institute (US)
- ORCID
- Maguire, Albert M.
- Simonelli, Francesca
- Pierce, Eric A.
- Pugh, Edward N.
- Mingozzi, Federico
- Banfi, Sandro
- Testa, Francesco
- Surace, Enrico M.
- Rossi, Settimio
- Arruda, Valder R.
- Konkle, Barbara
- Stone, Edwin
- Sun, Junwei
- Hertle, Richard
- Ma, Jian-xing
- Redmond, T. Michael
- Zhu, Xiaosong
- Shindler, Kenneth S.
- Maguire, Maureen G.
- Wright, J. Fraser
- Volpe, Nicholas J.
- Auricchio, Alberto
- High, Katherine A.
- Bennett, Jean
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-22
- Volume
- 358
- Issue
- 21
- Pages
- 2240-2248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2829748
- OpenAlex
- W2137222303
- Cited by
- 2,145
- References
- 27
- Citations by year
- 2026: 38 · 2025: 68 · 2024: 51 · 2023: 66 · 2022: 79 · 2021: 110 · 2020: 96 · 2019: 98 · 2018: 118 · 2017: 144 · 2016: 124 · 2015: 172 · 2014: 152 · 2013: 155 · 2012: 158
- FWCI
- 70.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Eye Institute (EY10820, R01EY010820)
- National Center for Research Resources (UL1RR024134)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, adeno-associated virus vectors, retinal pigment epithelium, macular hole, visual acuity, retinal function, adverse events, inherited retinal degeneration
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adult, Blindness, Carrier Proteins, Eye Proteins, Genetic Vectors, Humans, Injections, Mutation, Promoter Regions, Genetic, Reflex, Pupillary, Retina, Retinal Degeneration, Visual Acuity, Genetic Therapy, Gene Transfer Techniques, DNA, Complementary, cis-trans-Isomerases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.